Antios Therapeutics Inc.

Viral disease-focused Antios Therapeutics Inc. hopes to move its active site polymerase inhibitor nucleotide (ASPIN) ATI-2173 into a 12-month Phase IIb study later this year, which could provide the

Athenex Taps NCI TCRs For Solid Tumor Off-The-Shelf Therapy Athenex, Inc. announced a licensing agreement on 9 November with the US National Cancer Institute (NCI) to expand its development capabil

The biotechnology company creator and funder Flagship Pioneering and the Cystic Fibrosis Foundation announced a strategic partnership on 3 November under which the CF Foundation has committed up to